Multiple Myeloma: A Study of C-220 as a Single Treatment and in Combination with Other
What is the maximum tolerated dose, safety, and efficacy of CC-220 as a single therapy
and in combination with other treatments in subjects with Multiple Myeloma?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This is a multicenter, multi-country study consisting of two parts: Part 1) Evaluation
of dosing amounts of CC-220 alone, CC-220 in combination with DEX, CC-220 in combination
with DEX and DARA, CC-220 in combination with DEX and BTZ, and CC-220 in combination
with DEX and CFZ; Part 2) Expansion of the highest tolerated doses of CC-220 alone,
CC-220 in combination with DEX (DoubleT) for Relapsed Refractory Multiple Myeloma
and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.
Study Reference #: IMMY19114
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Stephanie Short
Phone: (585) 276-7885
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search